Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Incidence of Bell's Palsy After Coronavirus Disease (Covid-19) Vaccination: A Systematic Review and Meta-Analysis; [Incidencia De La Paralisis De Bell Despues De La Vacunacion Contra La Covid-19: Una Revision Sistematica Y Un Metanalisis] Publisher



Soltanzadi A1 ; Mirmosayyeb O2 ; Momeni Moghaddam A1 ; Ghoshouni H2 ; Ghajarzadeh M3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Radiology Department, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Universal council of epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran

Source: Neurologia Published:2024


Abstract

Objective: To estimate the pooled incidence of Bell's palsy after COVID-19 vaccination. Methods: PubMed, Scopus, EMBASE, Web of Science, and Google Scholar were searched by 2 independent researchers. We also searched the grey literature including references of the references and conference abstracts. We extracted data regarding the total number of participants, first author, publication year, the country of origin, sex, type of vaccines, and the number of patients who developed Bell's palsy after COVID-19 vaccination. Results: The literature search revealed 370 articles, subsequently deleting duplicates 227 remained. After careful evaluation of the full texts, 20 articles remained for meta-analysis. The most commonly administered vaccines were Pfizer followed by Moderna. In total, 4.54e+07 individuals received vaccines against COVID-19, and 1739 cases developed Bell's palsy. In nine studies, controls (individuals without vaccination) were enrolled. The total number of controls was 1 809 069, of whom 203 developed Bell's palsy. The incidence of Bell's palsy after COVID-19 vaccines was ignorable. The odds of developing Bell's palsy after COVID-19 vaccines was 1.02 (95% CI: 0.79-1.32) (I2 = 74.8%, P < .001). Conclusion: The results of this systematic review and meta-analysis show that the incidence of peripheral facial palsy after COVID-19 vaccination is ignorable and vaccination does not increase the risk of developing Bell's palsy. Maybe, Bell's palsy is a presenting symptom of a more severe form of COVID-19, so clinicians must be aware of this. © 2023 Sociedad Espanola de Neurologia
Related Docs
View other Related Docs
1. Multiple Sclerosis (Ms) and Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccines: A Systematic Review, Revue Neurologique (2023)
2. Acute Cns Demyelination in a Subject With Cerebellar Ataxia Following the First Dose of Covid-19 Vaccine; a Case Report, Human Vaccines and Immunotherapeutics (2021)
3. Presumed Partial Third Nerve Palsy After Covid-19 Vaccination: A Case Report; [احتمال فلج ناقص عصب سوم پس از واکسیناسیون کووید- :19گزارش یک مورد], Journal of Isfahan Medical School (2024)
4. Immunogenicity of Covid-19 Vaccines in Patients With Diabetes Mellitus: A Systematic Review, Frontiers in Immunology (2022)
5. Covid-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in Covid-19-Vaccinated Patients: A Multicenter Comparative Cohort Study, Arthroplasty Today (2022)
6. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
7. Cardiovascular Complications of Sars-Cov-2 Vaccines: An Overview, Cardiology and Therapy (2022)
8. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (6)
Masoud Etemadifar (5)
Other Related Docs
9. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)
10. Covid-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran, Vaccines (2022)
11. Cns Demyelinating Disease Following Inactivated or Viral Vector Sars-Cov-2 Vaccines: A Case Series, Vaccine (2023)
12. A Comprehensive Review on Various Aspects of Sars-Cov-2 (Covid-19) Vaccines, International Journal of Preventive Medicine (2022)
13. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
14. Topics and Users' Emotions on Social Media Regarding the Covid-19 Vaccine: A Systematic Review, Ethiopian Medical Journal (2023)
15. Vaccine-Associated Complications: A Comparative Multicenter Evaluation Among Dental Practitioners and Dental Students—Which Candidate Vaccine Is More Safe in Sars Cov Ii, Gam-Covid-Vac (Sputnik V), Chadox1 Ncov-19 (Astrazeneca), Bbv152 (Covaxin), or Bbibp-Corv(Sinopharm)?, Maxillofacial Plastic and Reconstructive Surgery (2022)
16. Covid-19 Breakthrough Infections Among Patients With Cancer Receiving Sinopharm Bibp Vaccine, International Journal of Cancer Management (2022)
17. Covid-19 Vaccination and Tinnitus: A Case Report, Journal of Kerman University of Medical Sciences (2023)
18. Importance of the Covid-19 Vaccine Booster Dose in Protection and Immunity, Vaccines (2022)
19. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
20. Association of Prior Covid‑19 Infection With Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran, International Journal of Preventive Medicine (2024)
21. Cardiovascular Complications of Covid-19 Vaccines: A Review of Case-Report and Case-Series Studies, Heart and Lung (2023)
22. Monitoring and Active Surveillance of Adverse Events Following the Booster Dose of Azd1222 Vaccine in People Vaccinated With Sinopharm Bbibp-Corv: A Cohort Study, BMC Public Health (2025)
23. The Effect of Covid-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran, Iranian Journal of Public Health (2022)
24. Sars-Cov-2 Serology Among People With Multiple Sclerosis on Disease-Modifying Therapies After Bbibp-Corv (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine, Multiple Sclerosis and Related Disorders (2022)
25. The Mrna Vaccines and Their Application to Combat Infectious Diseases and Cancers: A Review Article, Journal of Isfahan Medical School (2023)
26. Effect of Multiple Sclerosis Disease-Modifying Therapies on the Real-World Effectiveness of Two Doses of Bbibp-Corv (Sinopharm) Vaccine, Journal of the Neurological Sciences (2023)
27. Efficacy and Side Effects of Sputnik V, Sinopharm and Astrazeneca Vaccines to Stop Covid-19; a Review and Discussion, Immunopathologia Persa (2021)
28. Is Myasthenia Gravis a Real Complication of the Covid-19 Vaccine? a Case Report-Based Systematic Review, Canadian Journal of Infectious Diseases and Medical Microbiology (2022)
29. Third Covid-19 Vaccine Dose for People With Multiple Sclerosis Who Did Not Seroconvert Following Two Doses of Bbibp-Corv (Sinopharm) Inactivated Vaccine: A Pilot Study on Safety and Immunogenicity, Frontiers in Immunology (2023)
30. Unraveling the Mystery of Covid-19 Postvaccination Myocarditis: A Systematic Review of Current Cases, International journal of clinical practice (2022)
31. Effectiveness of Bbibp-Corv Vaccine in Preventing Sars-Cov2 Infection and Severe Outcomes in People Living With Multiple Sclerosis: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
32. A Prospective Cohort Study Protocol: Monitoring and Surveillance of Adverse Events Following Heterologous Booster Doses of Oxford Astrazeneca Covid-19 Vaccine in Previous Recipients of Two Doses of Sinopharm or Sputnik V Vaccines in Iran, BMC Public Health (2023)
33. Multiple Sclerosis Disease-Modifying Therapies and Covid-19 Vaccines: A Practical Review and Meta-Analysis, Journal of Neurology, Neurosurgery and Psychiatry (2022)
34. Safety, Acceptance, and Hesitancy of Covid-19 Vaccines Among High-Risk Sub-Populations: A Narrative Review, Journal of Pediatrics Review (2023)
35. Comparative Study of the Level of Neutralizing Antibodies in People Injecting 4 Types of Covid-19 Vaccine; [بررسیمقایسهایسطح آنتیبادیخنثیکنندهدر افراد تزریقکنندهی4نوع واکسن کووید-], Journal of Isfahan Medical School (2024)
36. Covid-19 Vaccination in Patients With Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to Covid-19: A Usidnet Report, Journal of Clinical Immunology (2024)
37. Is Coronavirus One of the New Etiologies of Facial Nerve Paralysis? a Case Report Study, Advanced Biomedical Research (2023)
38. Comparing the Consequences of Covid-19 Vaccination Between Central Nervous System (Cns) Demyelinating Diseases and Other Neurological Disorders, Vaccine (2024)
39. Guillain-Barre Syndrome (Gbs) After Severe/Critical Covid-19 or Covid-19 Vaccination, European journal of medical research (2025)
40. A Population-Based and Symptom-Based Covid-19 Prevalence Survey, Journal of Education and Health Promotion (2023)